

Neuropsychiatry of
Diffuse Lewy Body Dementia
&
Parkinson's Disease Dementia

KIEL ADAM MORRIS, DO
BROADLAWN GERIATRICS

1

Disclosures...

I have no financial or commercial interests to disclose.

Medications discussed will likely include off-label uses.

Limited data & approval → deference to expert consensus.

2

Why discuss this topic?

DLB 2nd most common dementia after Alzheimer's.
Parkinson's very often leads to MCI & Dementia.
Difficult to consolidate findings into diagnosis.
Easy to misdiagnose / miss diagnosis.
Disease-specific treatment considerations.

3

Inherent challenges in treatment

- Complex multi-system presentation & symptoms.
 - Cognitive, Psychiatric, Autonomic, Motor, etc.
- Patient-to-patient variability of presentation.
 - No "one size fits all" strategies.
- Symptoms vary throughout course of disease.
 - Need to be adaptive to changes.
- Limited data → limited treatments, pending research.
 - Recommendations often per expert consensus.
- Treatments may worsen other features.
 - (*delicate balancing act*)

4



- What I intend to cover
- Definitions & Terminology, e.g. Lewy Body Disease & "dementia".
- Briefly discuss underlying pathophysiology of Lewy Body Disease.
- Distinguish Parkinson Dementia (PDD) & Diffuse Lewy Body Dementia (DLB).
- Review key identifiable features that make PDD & DLB stand out.
- Discuss review treatments for cognitive & psychiatric symptoms.

5

Clinical Case

6


Major Neuro-Cognitive Disorder

"dementia"

- ▶ Disease state → impairs cognition → impairs function.
 - ▶ *Subjective* cognitive decline from previous baseline.
 - ▶ *Objective* multi-domain cognitive impairment.
 - ▶ *Instrumental* dysfunction due to impairments.
 - ▶ No equally viable contributors or differentials.
- ▶ Dementia is a severity point on a given disease continuum.
 - ▶ e.g., Alzheimer Disease = Pre-Clinical → Mild Impairment → Dementia.
 - ▶ Dementia stages = mild → moderate → severe → end stage.

7

"Lewy Body Diseases"

- ▶ **Diffuse Lewy Body Disease (DLB) & Parkinson's Disease Dementia (PDD)**.
 - ▶ Common denominator = **Lewy Bodies**
- ▶ **1 Year Rule** of onset in DLB, *locus → symptom*.
 - ▶ 



8

Neurotransmission

1. Lewy Body diseases manifest via destruction of neurons, nuclei, and pathways, as well as deficits or imbalances of neurotransmitters. To understand the pathophysiology we'll Zoom in on the synapse.



9

Alpha-Synuclein Function

► Hypothetical roles in **Dopamine (DA) neurotransmission**

- **Synthesis:** increased by disinhibiting tyrosine hydroxylase (TH).
- **Packaging:** facilitation of pre-synaptic vesicles via VMAT.
- **Transport:** modulates DA Transporter ergo synaptic [DA].


10

Alpha-Synuclein dysfunction


11

Errors Detected:
Processors [nuclei]
Signals [neurotransmitters]
Circuits [pathways]
Malfunction [symptoms]

12




13




14




15




16




17



18



19



20

68M brought in by wife for cognitive decline gradually progressive for the last year; some days significantly better than others. Symptoms include misplacing items, forgetting to take his pills, trouble balancing the check book, and increasing trouble navigating in the city. He'd previously been active in his wood shop, but has a hard time designing & completing projects. No psychiatric history, but in the last 1-2 months, he has become apathetic, withdrawn, and less facially expressive, leading PCP to start him on Escitalopram for suspected mild depression. They recently stopped sharing a bed due to him kicking in his sleep. He admits he sometimes sees a vivid figure of a cat as he wakes, and though they do not own any pets, he is not overly distressed by this. No physical symptoms aside from a slower gait. PMFSH & medications otherwise unremarkable.

21

Cholinesterase Inhibitors

Mechanism: Acetylcholinesterase inhibition leads to ↑ acetylcholine at the synapse.

Goal: ↑ cognition, ↓ BPSx.

Side Effects: GI (N/V/D), PNS (↓HR), Sleep ↓

Donepezil: start 5 mg PO once daily.
- ↑ 10 mg in 4 weeks if tolerated.

Rivastigmine: 4.6 mg TD once daily.
- ↑ 11 monthly as tolerated.

Galantamine: if above not tolerated.

Memantine

Mechanism: NMDA receptor antagonist. Preserves memory by blocking glutamate signal transmission.

Goal: ↓ excitotoxicity, preserve cognition/function.

Side Effects: confusion, dizziness, headache.

Dose (IR): start 5 mg, +5 mg/wk → target 20 mg.

Dose (ER): start 7 mg daily, +7 mg/wk → max 28 mg.

22

Anxiety

Pathophysiology: nuclei/pathways, NTs, Amygdala

Presentation: restless, sleepless, worried, phobic.

Course: often worse during "off periods"

Treatment:

- SsRIs:** e.g. Es/Citalopram, Sertraline
- SNRIs:** e.g. Venlafaxine (limited data)
- Mirtazapine:** NE, 5-HT, H1 neurotransmission ↑
- Buspirone:** 5HT_{1A} agonist ± D₂ antagonism?
- Benzos usually not recommended

Depression

Pathophysiology: DA & NE ↓ ± Reactive

Course: often mirrors motor symptoms
Related to ↓DA deficiency & Tx?

Diagnosis: easy to misinterpret symptoms

- Hypomotility → "emotionally withdrawn"
- Apathy → "avolitional / anhedonic".
- Sleep dx, e.g. hypersomnia, may be 1st.

Treatment:

- SsRIs** e.g. Sertraline reasonable 1st line
- SNRIs:** e.g. Venlafaxine & Duloxetine
- Bupropion:** NE & DA reuptake inhibitor
- Dopamine Rx** may improve depression
- ECT & **DBS** being studied.

23

Psychosis

Pathophys: complex: 5-HT, ACh, DA implicated.

Clinical: visual hallucinations, presence hallucinations, illusions, other modalities, delusions (paranoid).

Differentials: illusions, distortions of memory.

Treatment: not always needed if symptoms benign.

Our patient's hallucination did not bother him, but it probably didn't look like this →

So do we need to treat at this point?

Avoid D₂ antagonists; risk of sensitivity & mortality.

Conservative behavioral measures – limited data.

Wean Dopamine Rx gradually as follows:

- Anti-Cholinergics → MAO-B inhibitors
- Amantadine → dopamnergics
- COMT-inhibitors → Levodopa.

Cholinesterase Inhibitors: e.g. Donepezil.

Antipsychotics: w/caution if **distress** or **danger**.

Pimavanserin - 5HT_{2A/2C} antagonist, approved for PDD w/psychosis, not yet for DBL. \$\$\$

Clozapine & Quetiapine - D₂/5HT_{2A} blockers

- Dyskinesia risk low in both vs other SGAs
- Effect: Clozapine > Quetiapine
- Monitoring: Clozapine > Quetiapine

24

Sleep Disturbances

REM Sleep Behavior Disorder
Hypersomnia, 1° vs 2°
Insomnia, 1° vs 2°
Obstructive Sleep Apnea
Parkinsonism, nocturnal
Restless Legs Syndrome
Periodic Limb Movement

25

REM Sleep Behavior Disorder

Prevalence:
General Population ~1%
α-Synucleinopathies ≥ 50%
► May be prodromal
5-HT & NE meds may increase risk.

Interventions: safety → reversible factors → Pharmacotherapy

Diagnostic Criteria for RBD

- Repeated episodes of sleep-related vocalization and/or complex motor behaviors that occur during REM sleep.
- These behaviors are documented by polysomnography to occur during REM sleep or, based on clinical history of dream enactment, are presumed to occur during REM sleep without atonia (RSWA).
- The disturbance is not better explained by another sleep disorder, mental disorder, medication or substance abuse.

Pharmacotherapy:

- Melatonin** start 3 mg PO HS.
 - Effective range 6-18 mg.
- Clonazepam** start 0.25 mg PO HS.
 - Effective range 0.5-1 mg.

26

Dyssomnias, other

Hypersomnia: hygiene → evaluate / treat underlying causes:
Primary Insomnia → Melatonin; limited data on "z-drugs".
Caution: Mirtazapine & Trazodone may ↑ RSBd.
Obstructive Sleep Apnea: CPAP if indicated.
Nocturnal Parkinsonism: Levodopa (possible psychosis).
Restless Legs: Ropinirole vs Pramipexole w/caution.
Hypersomnia 2.0 – still super sleepy? Trial stimulants.
Modafinil: 100 mg qAM, may trial 200 mg after 1 week.
Methylphenidate: start low, go slow, ER formulations.

27

So...what do we do for our patient?

Cognitive: behavioral + pharmacologic.

- Compensatory behavioral interventions.
- Social support, e.g. delegating tasks.
- Donepezil 5 mg ± Memantine 5 mg.

Depression: assess carefully & treat if present.

- Truly depression vs mimicking sx?
- SSRI (Escitalopram) okay if helps.
- Could try SNRI, e.g. Venlafaxine.

REM Sleep Disorder: PSG for OSA/RLS/PLMS.

- Safety measures first and foremost.
- Trial **Melatonin** 3 mg HS, titrate.
- Clonazepam, low dose, caution.

Visual Hallucinations: do we really need to treat?

- Probably not in his particular case.
- Reserve for distress/danger.

Parkinsonism: do we need to treat now? or...

- Reserve for disabling or disruptive sx?
- Risk of worsening psychosis.

68M brought in by wife for cognitive decline gradually progressive for the last year; some days seem better than others. Symptoms include misplacing items, forgetting to take his pills, trouble balancing the check book, and increasing trouble navigating in the car. He'd previously been active in his wood shop, but has a hard time designing & completing projects. No psychiatric history, but he has become withdrawn and less socially expressive, leading PCP to start him on Escitalopram for suspected mild depression. They recently stopped sharing a bed due to him kicking in his sleep. He admits he sometimes sees a vivid figure of a cat as he wakes, and though they do not own any pets, he is not overly distressed by this. No physical symptoms aside from a slower gait. PMSH & medications otherwise unremarkable.

28

Sources

- Taylor, J.-P. (2020). New Evidence on the Management of Lewy Body Dementia. *Lancet Neurology*, 19(2), 157–169. [https://doi.org/10.1016/S1474-4422\(19\)30153-X](https://doi.org/10.1016/S1474-4422(19)30153-X)
- Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD) [published correction appears in *J Clin Sleep Med*. 2010 Apr 15;6(2):table of contents]. *J Clin Sleep Med*. 2010;6(1):85-95.
- Memory Loss, Alzheimer's Disease, and Dementia: A Practical Guide for Clinicians 3rd Ed, Chapter 8 – Dementia with Lewy Bodies, A. Budson, MD & P. Solomon, PhD
- Up To Date: Management of neuropsychiatric symptoms of dementia

29